1:45 PM (PT)
-
Our industry has faced a variety of geopolitical and economic issues that inject uncertainty into deal-making. We must now navigate an unprecedented wave of legislation, executive orders, and policies ...Breakout Session
-
Business Development and Investment
-
)
)
)
)
)
3:00 PM (PT)
-
In biotech, success often hinges on spotting opportunities before anyone else does. Some of the industry’s most impactful companies have been built with smart business development regardless of their ...Breakout Session
- Business Development and Investment
-
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM (PT)
-
After two years of a quiet IPO window, the biotech markets are showing renewed signs of life. A growing number of companies are testing public waters again — but with tighter investor scrutiny, leaner ...Breakout Session
- Business Development and Investment
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
.jpeg)
11:00 AM (PT)
-
As the next wave of patent cliffs loom, the pressure is on pharma to secure late-stage assets that deliver near-term value. Meanwhile, biotech leaders are navigating tighter capital markets and evolvi ...Breakout Session
- Business Development and Investment
-
-
As major patent expirations loom, pricing pressures intensify and R&D productivity comes under strain, large pharmaceutical companies are accelerating dealmaking to fill therapeutic and clinical-stage ...Breakout Session
- Business Development and Investment
-
-
Super SessionJoin Johnson & Johnson’s John Reed, MD, PhD, Executive Vice President, Innovative Medicine, R&D, and Nauman Shah, Global Head of Business Development, for a discussion on how the company brings togeth ...Super Session
- Business Development and Investment
-
.jpg/fit-in/120x9999/filters:no_upscale())
)
)
)
)
)
)
)
12:15 PM (PT)
-
Queensland, Australia is a rapidly growing biomedical innovation hub and a strategic gateway to the Asia-Pacific region. Anchored by world-class research institutes, hospitals, and industry, the state ...Global Innovation Hub Session 5A
1:45 PM (PT)
-
This data-driven session from BIO and its market intelligence partner, Norstella, will dive into the state of play for emerging biotech companies. From venture capital and public financing, deal-makin ...Breakout Session
- Business Development and Investment
-
)
.jpg/fit-in/120x9999/filters:no_upscale())
4:15 PM (PT)
-
AI-enabled discovery and multi-modal, human-centric datasets are driving the next wave of biopharma partnerships. Collaborations are expanding rapidly, characterized by larger upfronts, equity-linked ...Breakout Session
- Business Development and Investment
-
-
Many Western biopharma leaders look back and wish they had engaged earlier with the China story. A similar inflection point is now unfolding in Korea, and the time to engage early is now. South Korea ...Breakout Session
-
Emerging Opportunities in Global Markets
-
)
)
)
)
)
)
.jpeg)
.jpeg)
.jpg/fit-in/120x9999/filters:no_upscale())
)
.jpg/fit-in/120x9999/filters:no_upscale())
11:00 AM (PT)
-
As the global biotech ecosystem becomes increasingly interconnected, in-licensing has evolved into a core growth engine, with US–Asia deal-making and NewCo formation continuing to accelerate as compan ...Breakout Session
- Business Development and Investment
-
)
)
)
12:15 PM (PT)
-
Super SessionExplore how Saudi Arabia is building an integrated biotech ecosystem: agile regulation, targeted incentives, national genomics data assets, and enabling infrastructure to become a regional and global ...Super Session
- Emerging Opportunities in Global Markets
-
)
)
1:45 PM (PT)
-
Oncology continues to be the leading therapeutic area across the biopharma industry by almost all measures, including global drug sales, number of pipeline programs, venture capital dollar deployment, ...Breakout Session
-
Oncology
-
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
)
)
3:00 PM (PT)
-
For 87 years, our industry had to operate under an uncomfortable truth: over 90% of cancer drugs that "cure" mice routinely fail patients in clinical trials. In 2022, the FDA Modernization Act 2.0 too ...Breakout Session
- Oncology
-
-
AI technologies are no longer a peripheral concept in drug discovery – these platforms are a driving force for innovative companies reshaping the way we identify targets, and design, optimize, and val ...Breakout Session
-
AI and Digital Health
-
)
)
)
)
.jpg/fit-in/64x9999/filters:no_upscale())
)
)
.jpg/fit-in/120x9999/filters:no_upscale())
)
4:15 PM (PT)
-
Super SessionThis session will shed light on the recent acquisition of Akero Therapeutics by Novo Nordisk. The two panelists played a key role in forging this deal and will share their perspective on the journey t ...Super Session
- Business Development and Investment
-
)
9:00 AM (PT)
-
Even though orphan drugs currently account for almost 50% of all new medicine approved in USA and EU, many conditions still lack therapeutic options, and it has been estimated that 90-95% of the more ...Breakout Session
-
Orphan and Rare Disease
-
)
)
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}